language English
Article 2023 · 17 atıf

The acute effect of different NAD plus precursors included in the combined metabolic activators

Li, Xiangyu, Yang, Hong, Jin, Han, Turkez, Hasan, Ozturk, Gurkan, Doganay, Hamdi Levent, Zhang, Cheng, Nielsen, Jens, Uhlen, Mathias, Boren, Jan, Mardinoglu, Adil

Özet

NAD+ and glutathione precursors are currently used as metabolic modulators for improving the metabolic conditions associated with various human diseases, including non-alcoholic fatty liver disease, neurodegenerative diseases, mitochondrial myopathy, and age-induced diabetes. Here, we performed a one-day double blinded, placebo-controlled human clinical study to assess the safety and acute effects of six different Combined Metabolic Activators (CMAs) with 1 g of different NAD+ precursors based on global metabolomics analysis. Our integrative analysis showed that the NAD+ salvage pathway is the main source for boosting the NAD+ levels with the administration of CMAs without NAD+ precursors. We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN). In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky. In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD+ levels to improve altered metabolic conditions.

Anahtar Kelimeler
NAD plus precursors Serine Cysteine Carnitine Metabolomics Systems medicine GLUTATHIONE HOMEOSTASIS SUPPLEMENTATION PHOSPHOLIPIDS PACKAGE HEALTH DAMAGE TRIAL
WoS Kategorileri
Biochemistry & Molecular Biology Endocrinology & Metabolism
Sürdürülebilir Kalkınma Amaçları
Künye
Dergi
FREE RADICAL BIOLOGY AND MEDICINE
Yıl
2023
Cilt
205
Sayfa
77-89
ISSN
0891-5849
eISSN
1873-4596
DOI
10.1016/j.freeradbiomed.2023.05.032
WoS UID
WOS:001053802900001
Yayını aç (DOI)